AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates
AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised...
Eli Lilly
Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch
Eli Lilly and Company’s (NYSE: LLY) China unit announced a comprehensive organizational restructuring and key...
Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate
Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology...
Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly
Zuellig Pharma announced on 12 March 2026 the acquisition of all rights, title, and interest...
Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN...
Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...
Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
Insilico Medicine (HKG: 3696), a pioneer in generative artificial intelligence (AI)-driven drug discovery, announced a...
Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial
Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb...
Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
Eli Lilly and Company (NYSE: LLY) reported new long-term data from an open-label extension study...
Eli Lilly Submits Obesity Policy Recommendations at China Development Forum – Advocates for Weight Management in 15th Five‑Year Plan
Eli Lilly and Company (NYSE: LLY) submitted a comprehensive policy recommendation paper at the China...
Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...
Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect – Self‑Pay Pricing for Dual‑Target Obesity Drug
Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single‑patient‑use Zepbound...
Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion
Eli Lilly and Company (NYSE: LLY) announced a $3 billion investment in its China manufacturing operations...
Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
The WHO Foundation and Eli Lilly and Company (NYSE: LLY) announced a strategic partnership to...
Novo Nordisk’s CagriSema Fails Non‑Inferiority Test Against Lilly’s Zepbound in Phase III REDEFINE 4 Trial – 23% vs. 25.5% Weight Loss
Novo Nordisk A/S (NYSE: NVO) announced that its Phase III REDEFINE 4 study (NCT06131437) failed...
Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market
Eli Lilly and Company (NYSE: LLY) announced that China’s Center for Drug Evaluation (CDE) under...
Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
Eli Lilly (NYSE: LLY) and Incyte (NASDAQ: INCY) announced that the European Medicines Agency’s (EMA) Committee for...
Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...